EN DE
Watch Nexstim Oyj for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nexstim Oyj (NXTMH) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Nexstim Oyj stock €1.35, price €8.76, that is 84.6% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FI · ISIN FI4000506811

NO Nexstim Oyj logo Thin data Nov 9, 2026

Nexstim Oyj

NXTMH · HE
Very expensive, in a downtrend

Our calculation puts a fair price 85% below what the stock costs today.

Revenue last quarter +16% vs. a year ago.
Quality 55/100
Expensive Growth (revenue 5y +21.7 %/yr in EUR)
Thin margins · 0.4% net margin (TTM)
Moderate debt
Fair value €1.35 · Strongly overvalued
Negative free cash flow
Trails peers (3/10)
Narrow moat 26/100 · thin data
Thin data
Extreme value
Watch Nexstim Oyj for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€16.40 €2.18 Fair Value €1.35 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range €2.18 – €16.40 · fair‑value band €1.01 – €1.68 · the €8.76 price screens above the €1.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Nexstim in your weekly email

Every Wednesday you see whether Nexstim is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.

Show moreShow less

The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb.

The company markets and sells its diagnostics systems to universities and teaching hospitals.

It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer's disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems.

The company was incorporated in 2000 and is headquartered in Helsinki, Finland.

Stock analysis

Nexstim Oyj (NXTMH) currently trades at €8.76, while our model-based Fair Value estimate is €1.35, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of €2.17 per share, and 0 of the 12 models we run sit above the €8.76 price.

Bear case: the Economic Profit group reads lowest at €0.7400, and 12 of the 12 models stay below the price. Data coverage for this calculation is low.

Scenario range: €1.01 (bear) to €1.68 (bull), the price of €8.76 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Nexstim Oyj reported revenue of €11.0M in FY2025 versus €6.4M in FY2021, a compound +14.4%/yr. Reported net income was €573K in FY2025.

Key figures

Market cap €62.9M Micro · P/S ratio 5.49 · EPS (TTM) €−0.0200 · Net margin 0.4% · Return on equity 0.9% · Return on assets (EBIT) −3.5% (5-year average) · Operating margin −6.1% · Revenue (TTM) €11.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −85%, NXTMH screens richer than that median.

Fair Value models

Bear €1.01 Fair Value €1.35 Bull €1.68
Price €8.76 · Downside -84.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV €0.6300 €0.7100 €0.7700 74
ROIC Compounder €0.6600 €0.8700 €1.04 72
Residual Income €0.5200 €0.6100 €0.8200 71
All 12 models by family
Earnings-Based
Graham-Dodd €0.5400 €3.68 €5.15 63
Lynch FV €1.08 €1.54 €2.01 61
PEG = 1.0 €1.08 €1.54 €2.01 57
EPV €0.6300 €0.7100 €0.7700 74
Multiples
P/E Multiple €1.31 €1.74 €2.18 63
P/S Multiple €1.01 €1.35 €1.68 58
EV/EBIT €0.9100 €1.28 €1.65 65
EV/EBITDA €2.27 €3.09 €3.92 67
EV/Revenue €0.5900 €0.9300 €1.27 53
Economic Profit
Residual Income €0.5200 €0.6100 €0.8200 71
ROIC Compounder €0.6600 €0.8700 €1.04 72
Growth Earnings
Growth-Adj P/E €1.52 €2.17 €2.82 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 47
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 43
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 59
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+25.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
Start year 2020 (pandemic). Over 10 years: +15.8% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−30.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−30.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−81% → 6%
⚠ Revenue per share shrinking 30.4%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

NXTMH screens overvalued: fair value 85% below the price. Compare with Abbott Laboratories, →

Compare Nexstim Oyj with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −84.6% · Bottom 25%
Profitability
Return on equity (12 months) 0.9% · Below median
Return on assets 4.4% · Above median
Net margin (12 months) 0.4% · Below median
Operating margin (12 months) −6.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 16.1% · Above median
Balance sheet
Debt / equity 0.61× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 15.04× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 5.38× · Priciest 25%
EV/EBITDA 70.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)81 · sector 36
PAST (return on equity)3 · sector 17
HEALTH (low debt)69 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs NXTMH
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs NXTMH
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs NXTMH
DexCom, Inc DXCM $79.41 $87.35 +10% vs NXTMH
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs NXTMH
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs NXTMH
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs NXTMH
Abbott Laboratories, ABT $109.93 $75.28 −32% vs NXTMH
Medtronic plc MDT $101.80 $65.61 −36% vs NXTMH
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs NXTMH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nexstim Oyj: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nexstim Oyj Fair Value". https://www.fairvalue-calculator.com/stock/NXTMH

Frequently asked questions

Is Nexstim Oyj (NXTMH) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €1.35 versus a price of €8.76, about 85% lower (overvalued).
What is the fair value of NXTMH?
Our model-based fair value for Nexstim Oyj is €1.35 (as of Nov 9, 2026), built from audited fundamentals. The current price: €8.76.
What is the quality score of NXTMH?
Nexstim Oyj has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nexstim Oyj (NXTMH)?
Our model-based price target is the fair value of €1.35 (as of Nov 9, 2026) from 12 valuation models. Cautious scenario €1.01, optimistic scenario €1.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Nexstim Oyj stock forecast for 2026?
Our models put fair value at €1.35, about 85% lower versus a price of €8.76 (overvalued). Cautious scenario €1.01, optimistic scenario €1.68. The calculation is refreshed regularly with new filings.
What is the revenue of Nexstim Oyj (NXTMH)?
Nexstim Oyj reported trailing-twelve-month revenue of about €11.7M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Nexstim Oyj (NXTMH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nexstim Oyj it is €1.35 per share (as of Nov 9, 2026), against a price of €8.76. It is the blended result of 12 valuation models in 4 families (Earnings-Based, Multiples, Economic Profit, Growth Earnings).
Is Nexstim Oyj stock overvalued or undervalued in 2026?
As of Nov 9, 2026, NXTMH trades above its calculated fair value: price €8.76, fair value €1.35, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NXTMH?
No. The price is what the market pays today (€8.76); the fair value is what the company's own numbers justify (€1.35). For Nexstim Oyj the two are €7.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nexstim Oyj worth?
The market values Nexstim Oyj at about €62.9M (market capitalisation, as of Nov 9, 2026). Per share that is €8.76; our models calculate a fair value of €1.35 per share.
What do the bullish and bearish scenarios say about NXTMH?
Our models span a range for Nexstim Oyj: cautious scenario €1.01, base €1.35, optimistic €1.68 per share (as of Nov 9, 2026, price €8.76). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nexstim Oyj (NXTMH)?
Balance-sheet figures for Nexstim Oyj (as of Nov 9, 2026): return on equity 0.9%, debt of 0.61 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is NXTMH from its 52-week high?
Nexstim Oyj trades at €8.76, about 42% below its 52-week high of €15.05 and 8% above the low of €8.14 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €1.35 is for.
Which stocks are comparable to Nexstim Oyj?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nexstim Oyj stock attractive at the current price?
The data as of Nov 9, 2026: price €8.76, calculated fair value €1.35 (−85%), Quality Score 55/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NXTMH calculated?
We run Nexstim Oyj through 12 models from 4 families: Earnings-Based, Multiples, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €1.35 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Nexstim Oyj itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nexstim Oyj (NXTMH)?
The closing price on Nov 6, 2026 was €8.76. Our model-based fair value is €1.35, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nexstim Oyj right now?
The price sits above even our optimistic bull case (€1.68). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Nexstim Oyj

How large is the market capitalisation of Nexstim Oyj (NXTMH)?
The market capitalisation of Nexstim Oyj is €62.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nexstim Oyj (NXTMH)?
The price-to-sales ratio of Nexstim Oyj is 5.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nexstim Oyj (NXTMH)?
Earnings per share at Nexstim Oyj are €−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nexstim Oyj (NXTMH)?
The net margin of Nexstim Oyj is 0.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nexstim Oyj (NXTMH)?
The return on equity (ROE) of Nexstim Oyj is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nexstim Oyj (NXTMH)?
On an EBIT basis the return on assets of Nexstim Oyj is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nexstim Oyj (NXTMH)?
The operating margin of Nexstim Oyj is −6.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nexstim Oyj (NXTMH)?
Revenue at Nexstim Oyj is growing +16.1% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nexstim Oyj (NXTMH)?
Earnings per share at Nexstim Oyj are growing +822% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Nexstim Oyj (NXTMH) generate?
The free cash flow of Nexstim Oyj is −€37.3K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nexstim Oyj (NXTMH) carry?
The net debt of Nexstim Oyj is €1.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Nexstim Oyj in the live analysis

One click puts Nexstim Oyj on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.